Péptidos: ¿Milagro, moda o riesgo?

Por todos lados hoy día leemos de "los péptidos"  Aquí te explico qué son los péptidos, por qué algunos (como la insulina o los agonistas de GLP‑1R) tienen evidencia sólida y aprobación, y por qué otros que se promocionan en redes (BPC‑157, TB‑500, CJC‑1295, MOTS‑C, epitalón, GHK‑Cu, AOD9604) no tienen ensayos clínicos robustos en humanos y pueden implicar riesgos de pureza, seguridad y regulación. ¡Espero que te sirva para que no te inyectes algo que no tiene buena evidencia todavía! Te pongo tres cosas que tienes que preguntar cuando alguien te ofrezca un péptido...   Aquí te dejo los links de los que hablo:   Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495  https://pubmed.ncbi.nlm.nih.gov/40756949/ Lee E, Hossain M. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. (serie retrospectiva; 7/12 con alivio). https://pubmed.ncbi.nlm.nih.gov/34324435/ U.S. FDA. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 World Anti-Doping Agency. The 2026 Prohibited List. https://www.wada-ama.org/en/prohibited-list U.S. FDA. EGRIFTA (tesamorelin) Prescribing Information  https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf Meta-analysis: body composition, hepatic fat, metabolic and safety outcomes of tesamorelin in HIV-associated lipodystrophy. PubMed 2025. https://pubmed.ncbi.nlm.nih.gov/41545261/ The Regenerative Potential of GHK-Cu in Aesthetic Medicine: A Systematic Review. Aesthetic Surg J.  2026. https://pubmed.ncbi.nlm.nih.gov/42619529/ Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ Al-dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025 (in vitro; líneas de cáncer de mama vía ALT). Corrección: Biogerontology, 15 nov 2025. https://pubmed.ncbi.nlm.nih.gov/41240216/ Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. https://www.nature.com/articles/s41467-020-20790-0 MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov NCT07505745  https://clinicaltrials.gov/study/NCT07505745 AOD-9604 (Metabolic Pharmaceuticals): OPTIONS Study https://www.biospace.com/metabolic-pharmaceuticals-s-obesity-trial-update-first-100-subjects-complete-the-phase-2b-trial-of-aod9604 The Conversation. Influencers are promoting dangerous peptides on social media, and regulators are struggling to keep up. 2025. https://theconversation.com/influencers-are-promoting-dangerous-peptides-on-social-media-and-regulators-are-struggling-to-keep-up-282905